User menu

Validation of prognostic indices using the frailty model

Bibliographic reference Legrand, Catherine ; Duchateau, L. ; Janssen, P. ; Ducrocq, V. ; Sylvester, Richard J.. Validation of prognostic indices using the frailty model. In: Lifetime Data Analysis, Vol. 15, no. 1, p. 59-78 (2009)
Permanent URL
  1. Allard, Bernard, Fradet, TEtu, The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index, 10.1046/j.1464-410x.1998.00628.x
  2. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19: 453–473
  3. Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD (2007) Survival of invasive breast cancer according to the Nottingham Prognostic Index in case diagnosed in 1990–1999. Eur J Cancer 43: 1548–1555
  4. Blanchon F, Grivaux M, Asselain B et al (2006) 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 7: 829–836
  5. Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B (1992) Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organization for Research and Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. J Urol 148: 297–301
  6. Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of two European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153(Supplement): 934–941
  7. Cox DR (1972) Regression models in life-tables (with discussion). J Roy Stat Soc Ser B 34: 187–220
  8. Cramer H (1971) Mathematical methods of statistics. Princeton University Press, Princeton
  9. Duchateau L, Janssen P (2005) Understanding heterogeneity in mixed, generalized mixed and frailty models. Am Stat 59: 143–146
  10. Ducrocq V, Casella G, A Bayesian analysis of mixed survival models, 10.1186/1297-9686-28-6-505
  11. Ducrocq V, Sölkner J (1994) The Survival Kit, a FORTRAN package for the analysis of survival data. In: 5th World congress on genetics applied to livestock production, vol 22. Department of Animal Poultry Science, University of Guelph, Guelph, Ontario, Canada, pp 51–52
  12. Ducrocq V, Sölkner J (1998) The Survival Kit-V3.0, a package for large analysis of survival data. In: 6th World congress on genetics applied to livestock production, vol 27. Animal Genetics and Breeding Unit, University of New England, Armidale, Australia, pp 447–448
  13. Glidden DV, Vittinghoff E (2004) Modelling clustered survival data from multicentre clinical trials. Stat Med 23: 369–388
  14. Graf E, Schmoor C, Sauerbrei W, Schumacher M (1999) Assessment and comparison of prognostic classification schemes for survival data. Stat Med 18: 2529–2545
  15. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361–387
  16. Ibrahim Joseph G., Chen Ming-Hui, Sinha Debajyoti, Bayesian Survival Analysis, ISBN:9781441929334, 10.1007/978-1-4757-3447-8
  17. Justice Amy C., Assessing the Generalizability of Prognostic Information, 10.7326/0003-4819-130-6-199903160-00016
  18. Kendall M, Stuart A (1977) The advanced theory of statistics, vol 1: Distribution theory, 4th edn. London & High Wycombe, Charles Griffin & Company Limited
  19. Kurth KH, Schröder FH, Tunn U, Ay R, Pavone-Macaluso R, Debruyne F, De Pauw M, Dalesio O, Ten Kate F (1984) Adjuvant treatment of superficial transitional cell bladder carcinoma: preliminary results of an European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 132: 258–262
  20. Legrand C (2005) Assessing heterogeneity in multicenter clinical trials using the frailty model. PhD Thesis. Center for Statistics, Hasselt University
  21. Legrand C, Ducrocq V, Janssen P, Sylvester R, Duchateau L (2005) A Bayesian approach to jointly estimate center and treatment by center heterogeneity in a proportional hazards model. Stat Med 24: 3789–3804
  22. Matsuyama Y, Sakamoto J, Ohashi Y (1998) A Bayesian hierarchical survival model for the institutional effects in a multi-centre cancer clinical trial. Stat Med 17: 1893–1908
  23. Nelder J. A., Mead R., A Simplex Method for Function Minimization, 10.1093/comjnl/7.4.308
  24. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R (1995) Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer Results of a prospective randomized phase III study performed by the EORTC GU Group. EORTC Genitourinary Tract Cancer Cooperative Group. Eur Urol 27: 110–116
  25. Oosterlinck W, Kurth KH, Schröder FH, Butlinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage TaT1 papillary carcinoma of the bladder. J Urol 149: 749–752
  26. Putter H, Fiocco M, Geskus RB (2007) Tutorial in biostatistics: competing risks and multi-state models. Stat Med 26: 2389–2430
  27. Ripatti S, Larsen K, Palmgren J (2002) Maximum likelihood inference for multivariate frailty models using an automated Monte Carlo EM algorithm. Lifetime Data Anal 8: 349–360
  28. Royston P, Parmar MKB, Sylvester R (2004) Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. Stat Med 23: 907–926
  29. Schemper M (2003) Predictive accuracy and explained variation. Stat Med 22: 2299–2308
  30. Schemper M, Henderson R (2000) Predictive accuracy and explained variation in Cox regression. Biometrics 56: 249–255
  31. Schemper M, Stare J (1996) Explained variation in survival analysis. Stat Med 15: 1999–2012
  32. Simon R, Altman DG, Statistical aspects of prognostic factor studies in oncology, 10.1038/bjc.1994.192
  33. Sinha D, Ibrahim JG, Chen MH (2003) A Bayesian justification of Cox’s partial likelihood. Biometrika 90: 629–641
  34. Smith A, Skene AM, Shaw J, Naylor J, Dransfield M (1985) The implementation of the Bayesian paradigm. Commun Stat Theory Meth 14: 1079–1102
  35. Smith CT, Williamson PR, Marson AG (2005) Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat Med 24(9): 1307–1319
  36. Solal-Celigny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104: 1258–1265
  37. Spiegelhalter DJ, Abrams K, Myles JP (2004) Bayesian approaches to clinical trials and health care evaluation. Wiley, Chichester
  38. Sylvester RJ, Van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DWW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORT trials. Eur Urol 49: 466–477
  39. Tierney L, Kadane JB (1986) Accurate approximations for posterior moments and marginal densities. J Am Stat Assoc 81(391): 82–86
  40. Vaida F, Xu R (2000) Proportional hazards model with random effects. Stat Med 19: 3309–3324
  41. Van Houwelingen HC (2000) Validation, calibration, revision and combination of prognostic survival models. Stat Med 19: 3401–3415
  42. Witjes JA, Van der Meijden AP, Sylvester RJ, Debruyne FM, Van Aubel A, Witjes WP (1998) Long term follow up of an EORTC randomized prospecive trial comparing intravesical bacille Calmette-Guérin-RIVM and Mitomycin C in superficial bladder cancer. Urology 52: 403–410
  43. Yamaguchi T, Ohashi Y (1999) Investigating centre effects in a multi-centre clinical trial of superficial bladder cancer. Stat Med 18: 1961–1971
  44. Yamaguchi T, Ohashi Y, Matsuyama Y (2002) Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials. Stat Methods Med Res 11: 221–236